Sanibel Captiva Trust Company Inc. Lowers Position in GSK plc (NYSE:GSK)

Sanibel Captiva Trust Company Inc. decreased its position in shares of GSK plc (NYSE:GSK) by 10.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,633 shares of the pharmaceutical company’s stock after selling 1,718 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in GSK were worth $495,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Cypress Wealth Services LLC grew its stake in GSK by 23.8% in the fourth quarter. Cypress Wealth Services LLC now owns 11,966 shares of the pharmaceutical company’s stock worth $405,000 after purchasing an additional 2,301 shares during the period. Advisors Management Group Inc. ADV grew its position in shares of GSK by 6.1% in the 4th quarter. Advisors Management Group Inc. ADV now owns 91,530 shares of the pharmaceutical company’s stock worth $3,096,000 after buying an additional 5,259 shares during the period. San Luis Wealth Advisors LLC increased its stake in shares of GSK by 37.8% in the 4th quarter. San Luis Wealth Advisors LLC now owns 21,968 shares of the pharmaceutical company’s stock worth $743,000 after acquiring an additional 6,031 shares in the last quarter. Ignite Planners LLC lifted its position in GSK by 6.8% during the 4th quarter. Ignite Planners LLC now owns 18,965 shares of the pharmaceutical company’s stock valued at $635,000 after acquiring an additional 1,210 shares during the period. Finally, Marcum Wealth LLC boosted its stake in GSK by 6.7% during the fourth quarter. Marcum Wealth LLC now owns 9,366 shares of the pharmaceutical company’s stock worth $317,000 after acquiring an additional 591 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on GSK. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 0.0 %

GSK stock opened at $33.46 on Monday. GSK plc has a one year low of $31.72 and a one year high of $45.92. The business’s fifty day moving average is $34.02 and its 200 day moving average is $37.98. The stock has a market capitalization of $69.34 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were issued a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.70%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.